|
|
Post by joeypotsandpans on Sept 10, 2017 2:47:44 GMT -5
While we're at it with the oldie but goodie articles that are directly related to MNKD IMO, here's a beaut, while we're having discussions about incorrect labels and the individual(s)/murderer's behind them: libn.com/2016/11/23/poison-pills/Sorry Liane but as far as I'm concerned this has a direct correlation to "All About MNKD" and it's history to where we are now. Hell even Mike C. tweeted when Shkreli got sentenced, another POS that was part of the historical 3 ring circus surrounding the events with this company. |
|
|
|
Post by joeypotsandpans on Sept 10, 2017 2:05:39 GMT -5
|
|
|
|
Post by joeypotsandpans on Sept 9, 2017 19:11:55 GMT -5
Evidently he took offense to the alter ego comment so I deleted the previously posted comment here, it will be edited without the alter ego comment and re-posted on SA
|
|
|
|
Post by joeypotsandpans on Sept 8, 2017 15:02:08 GMT -5
My friends want to wait to get in, and I keep telling them if it hits $3-$5 it's going to move so fast it will be hard to get in...ive been telling them that since I bought more in the .80s. That reminds me of the time I thought the same thing with NFLX and PCLN when they were in the 3-5 price range and started to move and never looked back (regrets I've had a few)...with that in mind here is a classic in memory of MNKD's founding father for this friday afternoon RIP big guy, enjoy:  vimeo.com/91950218 |
|
|
|
Post by joeypotsandpans on Sept 7, 2017 15:24:15 GMT -5
Inside day within in an uptrend, what say ye nasty woman  .....inside days are indicative of indecision...who would be more undecided the entity that wouldn't/couldn't cover their position on 5/3 when the shares effectively traded at .13 cents or the new buyer(s) that have been accumulating the past 4 weeks...makes one wonder lol |
|
|
|
Post by joeypotsandpans on Sept 7, 2017 15:17:39 GMT -5
Urbanksy was from the prior regime so it would not be a surprise if this is coming from Mike and he has another sharp replacement. The PR may be waiting for the replacement to officially leave a current position to be able to make an announcement. Obviously the price action really didn't flinch so looks like it's a non-issue and actually may be construed positively with any announcement.
|
|
|
|
Post by joeypotsandpans on Sept 7, 2017 1:39:51 GMT -5
Sure, George, I'm still here, but large cap? We're lucky if we ever get to ten bucks ( and many of us would be pretty happy with considerably less). And of course, I smoke the hopium! And very happy you see things others can't - I do, too, but they usually involve unfortunate endings! Now Baba, I fear you could be the next Ronald Gerald Wayne  |
|
|
|
Post by joeypotsandpans on Sept 6, 2017 16:03:14 GMT -5
Continuing the consolidation of the run up/working off the over bought condition before next leg up. Short sale restriction parameter (alternative uptick rule) was lifted after yesterday close of trade so anticipate continued pitch and catch sales. Got my execution on the ladder trade, will be looking to swap out another 100 with any further pullback to the 1.85 area...on a separate note for anyone in EXAS looks like it is breaking into new highs and another leg up (believe there are some that have been in that for some time). I noticed on my previous 100 the other side offset with a purchase of 100 at one handle deeper in the money on the same expiry, either that or it was a huge coincidence Joey is typing! Mnkd real time volume today; 2,285,609 shares, $1.97 minus 7 cents. minus 3.43%
Joey is a better chart reader than I am. Is Joey a radiologist?
Haha, Joey is far from a radiologist, however, Joey's sons are an Oncologist and Pharmacist....my new avatar is twofold in honor of my oldest who is a proud member of SITC (should have listened to him when he suggested I buy KITE in the low 20's 3 yrs. ago) and because Joey is no longer in his RVW slumber, there is a new here and now BOOM with MNKD that woke him up;) .....regarding the charts, we all read them with our own interpretations that's what makes TA so very cool and also makes markets...some may anticipate breakouts and some may anticipate failures....keep doing what you're doing Peppy, you're very much appreciated by members on the board |
|
|
|
Post by joeypotsandpans on Sept 6, 2017 13:44:10 GMT -5
I would generally agree if there were liquidity, however, this stock has been washed out and there is no water left to wash....weak hands, hands that could not take the chinese water torture of days past, and those that have moved on have been long gone... .those that remain aren't giving up much of it now, except those that are happy to get their pre-split .50 back which under normal circumstances would be the former $2.00 support...the dark side will do whatever they can to hold that line as resistance now but there is a nice little IPA by Tapestry Brewing that I'll be taking down....It's name you may ask? Katie Bar the Door This is the new line in the sand, I put a bid in for another 100 option contracts (Feb '18 laddering up) anticipating an attempt at a push below 2.....considering we've run up almost 100% from just over 3 weeks ago we are very short term overbought so need to work off that a little bit and this area would make a lot of sense for a little breather. Enjoy the holiday weekend, continued thoughts and prayers to those hit hard in the wake of Harvey. Continuing the consolidation of the run up/working off the over bought condition before next leg up. Short sale restriction parameter (alternative uptick rule) was lifted after yesterday close of trade so anticipate continued pitch and catch sales. Got my execution on the ladder trade, will be looking to swap out another 100 with any further pullback to the 1.85 area...on a separate note for anyone in EXAS looks like it is breaking into new highs and another leg up (believe there are some that have been in that for some time). I noticed on my previous 100 the other side offset with a purchase of 100 at one handle deeper in the money on the same expiry, either that or it was a huge coincidence |
|
|
|
Post by joeypotsandpans on Sept 5, 2017 12:17:54 GMT -5
I only see two greens on my entire screen....MNKD & GLD (SPDR Gold Shares)....aren't they one and the same!? ....oh the irony of the markets. |
|
|
|
Post by joeypotsandpans on Sept 5, 2017 11:22:56 GMT -5
Oramed, thanks for the chuckle this AM....what a farce that one is, on a different note, nice to see relative strength (MNKD) vs. a broad market selloff, I plead that if buying to do so without using margin. The margin calls helped the short selling back in those down draft days, I would imagine most longs now have their shares banked w/o worry of margin or they hold options. LOL Oramed....good one MN!!!  |
|
|
|
Post by joeypotsandpans on Sept 3, 2017 14:03:46 GMT -5
Both would be nice, however, I believe only "ultra-rapid" would put Afrezza in a separate category. The label change should be as simple as categorizing it as Monomeric Insulin, and separating it from Hexameric Insulin, that in and of itself would distinguish it from the other current RAA's. See below (source: www.ebi.ac.uk/pdbe/widgets/QuipStories/insulin/insulin.pdf ) A spoonful of sugar helps the medicine go down... ..." But not if the medicine is insulin as this is administered by injection under the skin! With this
method, the rapid dilution of zinc and the pH change that take place when insulin is secreted
by the pancreas do not occur and stable hexamers remain, which leads to suboptimal drug
delivery. With the advent of recombinant technology, modified forms of insulin have been produced which are better suited as drugs compared to the wildtype human protein. A form in which residue 28 at the C-terminal end of the B chain is mutated from proline to aspartate (insulin aspart - NovoRapid) (PDB entries 1zeg, 1zeh or 1kei) (view-4) displays greater flexibility in the C-terminal region, disrupting the assembly of the insulin dimer and favouring the monomeric form. This leads to a more rapid transfer of the molecule from the subcutaneous injection site into the bloodstream. Similarly, the drug Humalog (PDB entries 1lph or 2kjj) (view- 4), sold by Eli Lily, has two amino acids swapped at the C- terminus of the B chain (Pro28 and Lys29 are changed to Lys28 and Pro29). This change also favours the monomeric form
whilst not affecting the activity of the hormone. In both cases, the hexameric form prevails in the presence of zinc and the high concentrations used for crystallization and drug storage, but
compared to wildtype insulin, monomerisation is much more rapid in vivo."
so forget about the fast, rapid, ultra-rapid....just classify as Monomeric and it would stand on the shelf by itself, that makes the most sense as it can't be touched or have to share the space with the others and would finally get it's due with the features and advantages of monomeric insulin and what Al knew since day 1. |
|
|
|
Post by joeypotsandpans on Sept 1, 2017 10:41:12 GMT -5
Have seen this before folks watch the traders take it right down without anything material. I would generally agree if there were liquidity, however, this stock has been washed out and there is no water left to wash....weak hands, hands that could not take the chinese water torture of days past, and those that have moved on have been long gone... .those that remain aren't giving up much of it now, except those that are happy to get their pre-split .50 back which under normal circumstances would be the former $2.00 support...the dark side will do whatever they can to hold that line as resistance now but there is a nice little IPA by Tapestry Brewing that I'll be taking down....It's name you may ask? Katie Bar the Door This is the new line in the sand, I put a bid in for another 100 option contracts (Feb '18 laddering up) anticipating an attempt at a push below 2.....considering we've run up almost 100% from just over 3 weeks ago we are very short term overbought so need to work off that a little bit and this area would make a lot of sense for a little breather. Enjoy the holiday weekend, continued thoughts and prayers to those hit hard in the wake of Harvey. |
|
|
|
Post by joeypotsandpans on Sept 1, 2017 9:52:53 GMT -5
IMO, the article is a little (actually, hugely) misleading. Izzy's firm, with over 2200 employees, with offices on several continents, and that manages $35 Billion in assets, took a peanut sized $1 million stake in MNKD. I think it's legitimately doubtful Izzy is even aware of this stake. May not be aware now but the employee that put the money to work will make him aware when they have huge returns after the label change, the coming PAH announcements, halt in pediatric studies after the positive results cause this FDA to fast track approval for children, etc. When the Sanofi rep told me two years ago that the insurance issue was the biggest obstacle I understood exactly what she was talking about as I got my script and shot down to CVS to get it filled only to have it turned down by United Healthcare. I was told that it would not receive tier 2 as that category had "its shelf full", it would need to obtain its own insulin category....fast forward two years and nothing will change things for this superior insulin like the label change will. You can't stop progress, they could only hope to contain it. This management team will ultimately prevail IMO, as I've stated this is a total management overhaul. Every afrezza user I know that has been on it for the last two years can't say enough about it, the brain trust behind the ADCOM knew what they were doing with the overwhelming thumbs up vote to getting this to market, the prior FDA admin sealed the two year obstacles for the company with the label they saddled it with. New chapter in this epic story unfolding IMO. Enjoy the rest of your day |
|
|
|
Post by joeypotsandpans on Sept 1, 2017 9:18:28 GMT -5
Thanks - this is pretty big news IMO - "This is a week that witnessed MNKD’s inhalable insulin treatment Afrezza step up in sales, true- but more importantly, the firm launched its highly-anticipated pediatric clinical trial." For the first time the analysts are talking speed along with it being inhaled - "Maxim analyst Jason Kolbert believes the firm is “transforming the diabetes market with inhalable insulin Afrezza,” which is the quickest-acting insulin available on the market, improving management of blood sugar as well as patient quality of life". It's big news IMO when a billionaire philanthropist that has similar cultural background to Al and a multi-billion hedge fund notices a company with MNKD's potential. However small relative to their assets under management it still opens a very nice supportive door to have a decent size hedge funds wind behind your sails, especially when you've been drifting at sea for awhile through stormy waters |
|
I still appreciate the time and effort the author spent explaining his example.
